Valuation : Veru Inc.

Market Cap 42.28M 36.36M 34.31M 31.26M 58.43M 4.04B 58.96M 409M 157M 2.05B 159M 155M 6.51B P/E 2026 *
-2.44x
P/E 2027 * -2.52x
Enterprise Value 42.28M 36.36M 34.31M 31.26M 58.43M 4.04B 58.96M 409M 157M 2.05B 159M 155M 6.51B EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
89.63%
Yield 2026 *
-
Yield 2027 * -
1 day+0.40%
1 week-6.04%
Current month-11.07%
1 month-10.11%
3 months-15.59%
6 months+0.81%
Current year+16.36%
1 week 2.46
Extreme 2.46
2.85
1 month 2.46
Extreme 2.46
2.85
Current year 2.05
Extreme 2.05
7.33
1 year 2.05
Extreme 2.05
7.33
3 years 2.05
Extreme 2.05
19.2
5 years 2.05
Extreme 2.05
245.5
10 years 2.05
Extreme 2.05
245.7
Manager TitleAgeSince
Chief Executive Officer 65 31/10/2016
Director of Finance/CFO 67 01/01/2013
Chief Tech/Sci/R&D Officer 64 01/04/2018
Director TitleAgeSince
Chairman 65 01/03/2018
Director/Board Member 68 01/10/2016
Director/Board Member 68 01/03/2018
Date Insider Type Main position Quantity % Market Cap. Importance
13/08/26 Buy

Chief Technology Officer

1,800 0.0112%
04/05/26 Free

Director

160,000 0.9969%
04/05/26 Free

Director

102,000 0.6355%
Change 5-day change 1-year change 3-year change Capi.($)
+0.40%-6.04%-35.49%-76.29% 42.28M
-0.25%-0.96%+45.25%+102.76% 68.52B
-1.09%-6.20%+30.50%+74.05% 62.88B
-1.61%+0.23%-12.99%+379.13% 28.13B
-2.74%-3.53%+26.13%+13.50% 25.56B
-2.13%-6.55%-4.81%-18.49% 24.65B
-2.39%-5.19%+17.75%-19.64% 19.81B
-1.86%+1.15%+205.44%+353.89% 17.69B
-1.37%-3.77%-9.38%+528.34% 14.66B
-1.21%-2.68%+52.64%+161.69% 14.45B
Average -1.43%-2.18%+31.50%+149.89% 27.64B
Weighted average by Cap. -1.34%-1.41%+35.49%+138.21%

Financials

2026 *2027 *
Net sales - -
Net income -25.1M -21.59M -20.37M -18.55M -34.68M -2.4B -35M -243M -93.35M -1.22B -94.26M -92.19M -3.87B -37.1M -31.91M -30.1M -27.42M -51.27M -3.55B -51.73M -359M -138M -1.8B -139M -136M -5.71B
Net Debt - -
Logo Veru Inc.
Veru Inc. is a late clinical-stage biopharmaceutical company focused on developing medicines for the treatment of metabolic diseases, oncology, and acute respiratory distress syndrome (ARDS). Its drug development program includes two late-stage novel small molecules: enobosarm and sabizabulin. Enobosarm, a selective androgen receptor modulator, is being developed for two indications: Phase 2b clinical QUALITY study of enobosarm as a treatment to augment fat loss and to prevent muscle loss in sarcopenic obese or overweight elderly patients receiving a GLP-1 RA who are at-risk for developing muscle atrophy and muscle weakness, and Phase 3 ENABLAR-2 clinical trial of enobosarm and abemaciclib for the treatment of androgen receptor positive, estrogen receptor positive and human epidermal growth factor receptor 2 negative metastatic breast cancer in the 2nd line setting. Sabizabulin, a microtubule disruptor, is being developed for treatment of hospitalized patients with viral-induced ARDS.
Employees
20
Date Price Change Volume
10/09/26 $2.490 +0.40% 134,393
09/09/26 $2.480 -3.88% 265,751
08/09/26 $2.580 -2.27% 1,343,294
04/09/26 $2.640 -0.38% 143,543
03/09/26 $2.650 -3.64% 75,945
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
2.480USD
Average target price
24.50USD
Spread / Average Target
+887.90%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. VERU Stock
40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!